Daiwa Capital Initiates Coverage On Legend Biotech with Buy Rating
Portfolio Pulse from richadhand@benzinga.com
Daiwa Capital analyst Wilfred Yuen initiates coverage on Legend Biotech (NASDAQ:LEGN) with a Buy rating.
May 22, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Daiwa Capital analyst Wilfred Yuen initiates coverage on Legend Biotech with a Buy rating, indicating a positive outlook for the stock.
The Buy rating initiated by Daiwa Capital's analyst Wilfred Yuen suggests a positive outlook for Legend Biotech's stock. This rating indicates that the analyst believes the stock is undervalued and has potential for growth in the short term. As a result, this news is likely to have a positive impact on LEGN's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100